[Objective] This study aimed to investigate the inhibitory effect of buddle- jasaponin IV on growth of hepatocarcinoma 22 （H22） tumor in mice. [Method] The H= tumor cells were transplanted in the right axillary skin...[Objective] This study aimed to investigate the inhibitory effect of buddle- jasaponin IV on growth of hepatocarcinoma 22 （H22） tumor in mice. [Method] The H= tumor cells were transplanted in the right axillary skins of mice. The tumor- bearing mice were randomly divided into five groups, including control group, CTX group （20.0 mg/kg） and buddlejasaponin IV treatment groups （0.25, 0.50 and 1.00 mg/kg）. There were 10 mice in each group. During the treatment, the body weights and survivals of mice in all groups were recorded. The buddlejasaponin IV was in- jected into the abdominal cavities of mice, which lasted for 10 consecutive days. All the mice were slaughtered the next day. The tumors in the abdominal cavities were tanked out and weighed. The tumor inhibition rate, spleen index and thymus index, as well as SOD activity, MDA content, GGT activity and AKP activity in serum were determined. [Result] Compared with the control group, the high- and middle- dosage buddlejasaponin IV treatment groups all showed significant （P〈0.01） inhibito- ry effects on transplanted H22 tumor in mice with tumor inhibition rates of 56.96% and 50.63%, respectively. Compared with those in the control group, the SOD ac- tivity of mice in the high-dosage buddlejasaponin IV treatment group was significant- ly increased （P〈0.05）, and the MDA contents, GGT and AKP activities in mice in the high-, middle- and low-dosage buddlejasaponin IV treatment groups were all sig- nificantly reduced （P〈0.01）. There were no significant differences in all the indexes, except SOD activity, between the CTX and control groups. [Conclusion] Buddlejas- aponin IV has certain inhibitory effect on H22 tumor, of which the mechanism might be related to antioxidation capacity in body.展开更多
AIM： To investigate the antitumor and synergistic effect of Chinese medicine “Bushen huayu jiedu recipe” （recipe for invigorating the kidney, removing blood stasis and toxic substances） and chemotherapy on mice h...AIM： To investigate the antitumor and synergistic effect of Chinese medicine “Bushen huayu jiedu recipe” （recipe for invigorating the kidney, removing blood stasis and toxic substances） and chemotherapy on mice hepatocarcinoma. METHODS： Bushen huayu jiedu recipe （BSHYJDR） consisting of Chinese Cassia Bark, Psoralea, Zedoary, Rhubarb, etc. is equal to 1.5 g/mL liquid of originated herbs after being decoded, filtered, and concentrated. Kunming mice, weighing 18-22 g, were injected with 0.2 mL ascitic hepatocarcinoma H22 containing 1 × 10^7 cells/mL into armpit of the right forelimb of mice. After 24 h, the mice were weighed and randomly divided into tumor-bearing model control group, cisplatin （DDP） group, BSHYJDR high dosage group, low dosage BSHYJDR group, DDP combined with high and low dosage BSHYJDR group, 10 mice in each group. DDP group received injection intraperitoneally （ip） at the dosage of 1 mg/kg （equal to 1/10 LD50）, once a day for 4 d. High and low dosage BSHYJDR groups received intragastric BSHYJDR at the dosages of 26.6 and 13.3 g/kg （20 and 10 times each of clinical adult dosage） respectively, while tumor-bearing model group received the equal volume of distilled water once a day for 10 d. On the 11^th d, the mice were weighed and killed, then the tumor was dissected and weighed, the repression rate （RR） was calculated according to the mean weight of tumor （MWT）. RESULTS： Compared to the model group （MWT： 1.30±0.73）, DDP group （MWT： 0.41±0.09, RR： 68.46%） had a significant difference in the inhibition of hepatocarcinoma H22 （P〈0.01）. High dosage BSHYJDR group （MWT： 0.69±0.29, RR： 46.92%） also had a significant difference in inhibition （P〈0.05）, while no difference was found in low dosage BSHYJDR group （MVVT： 0.85±0.34, RR： 34.62%） （P〉0.05）. When DDP was combined with high dosage BSHYJDR （MWT： 0.29±0.17, RR： 77.69%） and low dosage BSHYJDR （MWT： 0.38±0.21, RR： 70.77%） respectively, we could see improvement of the inhibition effect of DDP on transplanted hepatocarcinoma H22. DDP combined with high dosage BSHYJDR had a significant difference （P〈0.001） compared to DDP, while DDP combined with low dosage BSHYJDR only had a little improvement that is not remarkable. CONCLUSION： Chinese medicine BSHYJDR in combination with chemotherapy can inhibit transplanted hepatocarcinorna in mice.展开更多
Objective： To investigate the antitumor effect of dendritic cell （DC） modified by gp96-peptide complexes both in vitro and in vivo. Methods：Gp96-peptide complexes were acquired from H22 liver cancer cells in mice....Objective： To investigate the antitumor effect of dendritic cell （DC） modified by gp96-peptide complexes both in vitro and in vivo. Methods：Gp96-peptide complexes were acquired from H22 liver cancer cells in mice. DC were cultured from bone marrow cells and modified by gp96-peptide complexes. Spleen lymphocytes of mice were activated by modified DC and the cytotoxicity were detected by ^51Cr release method. Modified DC, gp96-peptide complexes and inactivated H22 cells were injected into mice bearing H22 liver cancer cells to observe the levels of IL-10, IFN-y in serum and the alteration of proportions of CD8^＋-IFNy^＋ and CD8^＋-IL-10^＋ cells, CD4^＋-IFNy^＋ and CD4^＋-IL-10^＋ cells. Results： DC modified by gp96-peptide complexes can activate spleen lymphocyte and the latter can specifically kill H22 cells but not Ehrilich ascites carcinoma cells. Modified DC can improve the host＇s antitumor immune response and the proportions of Thl cells, inhibiting tumor growth. Conclusion： Gp96-peptide complexes can activate DC effectively, making DC a good vaccine.展开更多
基金Supported by Bagui Scholar Program of GuangxiScientific Research and Technological Development Program of Guilin(20110201)Open Fund of Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization(181H2011-03)~~
文摘[Objective] This study aimed to investigate the inhibitory effect of buddle- jasaponin IV on growth of hepatocarcinoma 22 （H22） tumor in mice. [Method] The H= tumor cells were transplanted in the right axillary skins of mice. The tumor- bearing mice were randomly divided into five groups, including control group, CTX group （20.0 mg/kg） and buddlejasaponin IV treatment groups （0.25, 0.50 and 1.00 mg/kg）. There were 10 mice in each group. During the treatment, the body weights and survivals of mice in all groups were recorded. The buddlejasaponin IV was in- jected into the abdominal cavities of mice, which lasted for 10 consecutive days. All the mice were slaughtered the next day. The tumors in the abdominal cavities were tanked out and weighed. The tumor inhibition rate, spleen index and thymus index, as well as SOD activity, MDA content, GGT activity and AKP activity in serum were determined. [Result] Compared with the control group, the high- and middle- dosage buddlejasaponin IV treatment groups all showed significant （P〈0.01） inhibito- ry effects on transplanted H22 tumor in mice with tumor inhibition rates of 56.96% and 50.63%, respectively. Compared with those in the control group, the SOD ac- tivity of mice in the high-dosage buddlejasaponin IV treatment group was significant- ly increased （P〈0.05）, and the MDA contents, GGT and AKP activities in mice in the high-, middle- and low-dosage buddlejasaponin IV treatment groups were all sig- nificantly reduced （P〈0.01）. There were no significant differences in all the indexes, except SOD activity, between the CTX and control groups. [Conclusion] Buddlejas- aponin IV has certain inhibitory effect on H22 tumor, of which the mechanism might be related to antioxidation capacity in body.
基金Supported by the Postdoctoral Science Foundation of China, No. [2001] 5
文摘AIM： To investigate the antitumor and synergistic effect of Chinese medicine “Bushen huayu jiedu recipe” （recipe for invigorating the kidney, removing blood stasis and toxic substances） and chemotherapy on mice hepatocarcinoma. METHODS： Bushen huayu jiedu recipe （BSHYJDR） consisting of Chinese Cassia Bark, Psoralea, Zedoary, Rhubarb, etc. is equal to 1.5 g/mL liquid of originated herbs after being decoded, filtered, and concentrated. Kunming mice, weighing 18-22 g, were injected with 0.2 mL ascitic hepatocarcinoma H22 containing 1 × 10^7 cells/mL into armpit of the right forelimb of mice. After 24 h, the mice were weighed and randomly divided into tumor-bearing model control group, cisplatin （DDP） group, BSHYJDR high dosage group, low dosage BSHYJDR group, DDP combined with high and low dosage BSHYJDR group, 10 mice in each group. DDP group received injection intraperitoneally （ip） at the dosage of 1 mg/kg （equal to 1/10 LD50）, once a day for 4 d. High and low dosage BSHYJDR groups received intragastric BSHYJDR at the dosages of 26.6 and 13.3 g/kg （20 and 10 times each of clinical adult dosage） respectively, while tumor-bearing model group received the equal volume of distilled water once a day for 10 d. On the 11^th d, the mice were weighed and killed, then the tumor was dissected and weighed, the repression rate （RR） was calculated according to the mean weight of tumor （MWT）. RESULTS： Compared to the model group （MWT： 1.30±0.73）, DDP group （MWT： 0.41±0.09, RR： 68.46%） had a significant difference in the inhibition of hepatocarcinoma H22 （P〈0.01）. High dosage BSHYJDR group （MWT： 0.69±0.29, RR： 46.92%） also had a significant difference in inhibition （P〈0.05）, while no difference was found in low dosage BSHYJDR group （MVVT： 0.85±0.34, RR： 34.62%） （P〉0.05）. When DDP was combined with high dosage BSHYJDR （MWT： 0.29±0.17, RR： 77.69%） and low dosage BSHYJDR （MWT： 0.38±0.21, RR： 70.77%） respectively, we could see improvement of the inhibition effect of DDP on transplanted hepatocarcinoma H22. DDP combined with high dosage BSHYJDR had a significant difference （P〈0.001） compared to DDP, while DDP combined with low dosage BSHYJDR only had a little improvement that is not remarkable. CONCLUSION： Chinese medicine BSHYJDR in combination with chemotherapy can inhibit transplanted hepatocarcinorna in mice.
基金Supported by National Natural Science Foundation of Chi-na (NO.30200369)
文摘Objective： To investigate the antitumor effect of dendritic cell （DC） modified by gp96-peptide complexes both in vitro and in vivo. Methods：Gp96-peptide complexes were acquired from H22 liver cancer cells in mice. DC were cultured from bone marrow cells and modified by gp96-peptide complexes. Spleen lymphocytes of mice were activated by modified DC and the cytotoxicity were detected by ^51Cr release method. Modified DC, gp96-peptide complexes and inactivated H22 cells were injected into mice bearing H22 liver cancer cells to observe the levels of IL-10, IFN-y in serum and the alteration of proportions of CD8^＋-IFNy^＋ and CD8^＋-IL-10^＋ cells, CD4^＋-IFNy^＋ and CD4^＋-IL-10^＋ cells. Results： DC modified by gp96-peptide complexes can activate spleen lymphocyte and the latter can specifically kill H22 cells but not Ehrilich ascites carcinoma cells. Modified DC can improve the host＇s antitumor immune response and the proportions of Thl cells, inhibiting tumor growth. Conclusion： Gp96-peptide complexes can activate DC effectively, making DC a good vaccine.
